Sanofi (SNYN) - Net Assets
Based on the latest financial reports, Sanofi (SNYN) has net assets worth MX$69.57 Billion MXN (≈ $4.00 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (MX$129.06 Billion ≈ $7.43 Billion USD) and total liabilities (MX$59.49 Billion ≈ $3.42 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SNYN capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | MX$69.57 Billion |
| % of Total Assets | 53.9% |
| Annual Growth Rate | 1.93% |
| 5-Year Change | 3.88% |
| 10-Year Change | 24.23% |
| Growth Volatility | 4.37 |
Sanofi - Net Assets Trend (2013–2025)
This chart illustrates how Sanofi's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see SNYN stock market capitalisation.
Annual Net Assets for Sanofi (2013–2025)
The table below shows the annual net assets of Sanofi from 2013 to 2025. Also explore SNYN net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | MX$71.71 Billion ≈ $4.13 Billion |
-7.90% |
| 2024-12-31 | MX$77.86 Billion ≈ $4.48 Billion |
+4.71% |
| 2023-12-31 | MX$74.35 Billion ≈ $4.28 Billion |
+1.14% |
| 2022-12-31 | MX$73.51 Billion ≈ $4.23 Billion |
+6.49% |
| 2021-12-31 | MX$69.03 Billion ≈ $3.97 Billion |
+9.32% |
| 2020-12-31 | MX$63.15 Billion ≈ $3.63 Billion |
+6.83% |
| 2019-12-31 | MX$59.11 Billion ≈ $3.40 Billion |
+0.12% |
| 2018-12-31 | MX$59.03 Billion ≈ $3.40 Billion |
+1.33% |
| 2017-12-31 | MX$58.26 Billion ≈ $3.35 Billion |
+0.93% |
| 2016-12-31 | MX$57.72 Billion ≈ $3.32 Billion |
-0.83% |
| 2015-12-31 | MX$58.21 Billion ≈ $3.35 Billion |
+3.45% |
| 2014-12-31 | MX$56.27 Billion ≈ $3.24 Billion |
-1.34% |
| 2013-12-31 | MX$57.03 Billion ≈ $3.28 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sanofi's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | MX$71.38 Billion | 100.00% |
| Total Equity | MX$71.38 Billion | 100.00% |
Sanofi Competitors by Market Cap
The table below lists competitors of Sanofi ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Spotify Technology SA
NYSE:SPOT
|
$100.37 Billion |
|
Equinix Inc
NASDAQ:EQIX
|
$100.78 Billion |
|
GlaxoSmithKline plc
MX:GSKN
|
$100.93 Billion |
|
CVS Health Corp
NYSE:CVS
|
$101.04 Billion |
|
CME Group Inc
NASDAQ:CME
|
$100.01 Billion |
|
State Bank of India
NSE:SBIN
|
$99.45 Billion |
|
HDFC Bank Limited
F:HDFA
|
$99.16 Billion |
|
Adobe Systems Incorporated
NASDAQ:ADBE
|
$98.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sanofi's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 77,507,000,000 to 71,376,000,000, a change of -6,131,000,000 (-7.9%).
- Net income of 7,813,000,000 contributed positively to equity growth.
- Dividend payments of 4,772,000,000 reduced retained earnings.
- Share repurchases of 5,030,000,000 reduced equity.
- New share issuances of 177,000,000 increased equity.
- Other factors decreased equity by 4,319,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | MX$7.81 Billion | +10.95% |
| Dividends Paid | MX$4.77 Billion | -6.69% |
| Share Repurchases | MX$5.03 Billion | -7.05% |
| Share Issuances | MX$177.00 Million | +0.25% |
| Other Changes | MX$-4.32 Billion | -6.05% |
| Total Change | MX$- | -7.91% |
Book Value vs Market Value Analysis
This analysis compares Sanofi's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.30x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 15.69x to 12.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | MX$46.32 | MX$727.00 | x |
| 2018-12-31 | MX$47.27 | MX$727.00 | x |
| 2019-12-31 | MX$47.00 | MX$727.00 | x |
| 2020-12-31 | MX$50.37 | MX$727.00 | x |
| 2021-12-31 | MX$54.83 | MX$727.00 | x |
| 2022-12-31 | MX$58.01 | MX$727.00 | x |
| 2023-12-31 | MX$59.17 | MX$727.00 | x |
| 2024-12-31 | MX$61.83 | MX$727.00 | x |
| 2025-12-31 | MX$59.10 | MX$727.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sanofi utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.95%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.72%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.78x
- Recent ROE (10.95%) is above the historical average (9.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 6.53% | 11.88% | 0.33x | 1.69x | MX$-1.97 Billion |
| 2014 | 7.82% | 13.72% | 0.33x | 1.74x | MX$-1.22 Billion |
| 2015 | 7.39% | 12.30% | 0.34x | 1.76x | MX$-1.52 Billion |
| 2016 | 8.18% | 13.57% | 0.33x | 1.82x | MX$-1.05 Billion |
| 2017 | 14.52% | 23.30% | 0.36x | 1.72x | MX$2.63 Billion |
| 2018 | 7.31% | 12.07% | 0.32x | 1.89x | MX$-1.58 Billion |
| 2019 | 4.76% | 7.46% | 0.33x | 1.91x | MX$-3.09 Billion |
| 2020 | 19.55% | 32.95% | 0.33x | 1.82x | MX$6.01 Billion |
| 2021 | 9.06% | 15.89% | 0.33x | 1.75x | MX$-645.10 Million |
| 2022 | 9.19% | 14.81% | 0.36x | 1.70x | MX$-594.40 Million |
| 2023 | 7.29% | 12.98% | 0.33x | 1.71x | MX$-2.00 Billion |
| 2024 | 7.17% | 12.55% | 0.33x | 1.71x | MX$-2.19 Billion |
| 2025 | 10.95% | 16.72% | 0.37x | 1.78x | MX$675.40 Million |
Industry Comparison
This section compares Sanofi's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $33,473,666,667
- Average return on equity (ROE) among peers: 33.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sanofi (SNYN) | MX$69.57 Billion | 6.53% | 0.86x | $100.25 Billion |
| AstraZeneca PLC (AZNN) | $37.06 Billion | 8.87% | 1.60x | $290.50 Billion |
| GlaxoSmithKline plc (GSKN) | $7.81 Billion | 69.59% | 4.39x | $100.93 Billion |
| Novartis AG (NVSN) | $55.55 Billion | 21.12% | 1.13x | $265.74 Billion |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, ty… Read more